Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

ternal affairs and general counsel;  Scott Brun, vice president of clinical development;  and Larry Peepo, vice president of investor relations.  The call will be webcast through AbbVie's Investor Relations Web site at www.abbvieinvestor.com.  An archived edition of the call will be available after 11:00 a.m. Central time.

Non-GAAP Financial Results Financial results for 2013 are presented on both a reported and a non-GAAP basis.  Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period.  Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release.  AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business.  Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.  The company's 2013 financial guidance is also being provided on both a reported and a non-GAAP basis. 

Forward-Looking StatementsSome statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements.  AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, challenges to intell
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. AbbVie Named a Science Top Employer
2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. AbbVie Declares Quarterly Dividend
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... products may protect against inflammation. Such were ... trial on the effects of processed tomatoes on ... men and women, presented by one of the ... 19, 2009 at the Experimental Biology meeting held ...
... Ability of PS-Targeting Antibodies to Reverse the Immune ... Microenvironment and Mobilizing Key Components of the Immune ... Stimulate Dendritic Cell Maturation, Inflammatory Cytokine and Chemokine ... and TUSTIN, Calif., April 21 Peregrine Pharmaceuticals, ...
Cached Medicine Technology:Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting 2Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting 3Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 3Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 4Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 5Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 6Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 7
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
(Date:4/17/2014)... 10 million older Americans suffer from depression, often brought ... new research a project that followed the lives ... found that Internet use among the elderly can ... percent. , "That,s a very strong effect," said Shelia ... studies and media who led the project. "And it ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Feb. 4 Pulse Systems announced today ... the International,Organization for Standardization (ISO) quality systems ... "Achievement of these highly-regarded ... contract manufacturing services to the,medical device industry, ...
... (Nasdaq: KNSY ), a leading medical technology company ... of medical procedures, today announced the resignation of Mr. Jeffrey ... its Board of Directors.Mr. Smith became a director of Kensey ... Corporate Governance and Nominating Committee as well as a member ...
... Oxford, UK, 04 February 2009 The journal ... publication, has announced the winner of the 2008 David ... Persson and Jan van der Linden from the Karolinska ... decrease the risk of surgical site infection" was judged ...
... Md., February 4, 2009 With counterfeit and adulterated ... United States and worldwide, the U.S. Pharmacopeial (USP) Convention ... products that have been involved in episodes of adulteration ... these standards, for the blood thinner heparin and the ...
... EPA/DHA and 170% Daily Requirement of Vitamin EPARAMUS, N.J., Feb. ... today announced that it will launch Smart Balance(TM) Milk in ... and New England during the first quarter of 2009. ... in Florida and Georgia, tastes rich and creamy, is low ...
... in Four Americans Show Features Real People with Real Stories, ... and Denver Broncos, Quarterback Jay CutlerWESTPORT, Conn., Feb. 4 ... new 2009 television schedule for dLifeTV , ... with diabetes, airing every Sunday on CNBC at 7:00PM ET, ...
Cached Medicine News:Health News:Pulse Systems Receives Dual Certification Under ISO 13485:2003 and ISO 9001:2008 2Health News:Kensey Nash Announces Director Resignation 2Health News:USP announces new standards to protect patients from counterfeit and adulterated medicines 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 3Health News:dLifeTV Announces New Season Programming and Celebrity Guests; Only Nationally-Broadcast Program About Diabetes Celebrates 5th Year and 200th Show 2Health News:dLifeTV Announces New Season Programming and Celebrity Guests; Only Nationally-Broadcast Program About Diabetes Celebrates 5th Year and 200th Show 3
1000L...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
Inquire...
Medicine Products: